Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor
Matthew R. Janes(University of California, Irvine), Collin Vu(University of California, Irvine), Jose J. Limon(Institute of Immunology), S. Tiong Ong(Singapore General Hospital), Marina Konopleva(The University of Texas MD Anderson Cancer Center), Raymond J. Lim(University of California, Los Angeles), Christian Rommel(Merck Serono (Switzerland)), Sharmila Mallya(University of California, Irvine), Lomon So(University of Washington), Melissa A Chavez(University of California, Irvine), Yi Liu(Yangtze University), Jing Chen(Case Western Reserve University), Michael B. Lilly(University of California, Irvine), Michael Martin(Intel (United States)), Pingda Ren(Intel (United States))
Cited by 338
Related Papers
2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party
|Blood|2021|714
PAX5-driven subtypes of B-progenitor acute lymphoblastic leukemia
|Nature Genetics|2019|616
Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Nonrandomized, Open-Label, Phase II Study
|Cancer Discovery|2018|570
Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML
|Blood|2008|512
Ibrutinib and Venetoclax for First-Line Treatment of CLL
|New England Journal of Medicine|2019|502